Use of a quinazoline compound in preparing a medicament against flaviviridae virus

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9133138
APP PUB NO 20130261139A1
SERIAL NO

13992870

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chao, Bo Shanghai, CN 5 24
He, Peilan Shanghai, CN 2 19
Hu, Youhong Shanghai, CN 12 71
Ji, Feihong Shanghai, CN 2 2
Li, Dewen Shanghai, CN 4 2
Tang, Wei Shanghai, CN 189 2867
Tong, Xiankun Shanghai, CN 3 2
Zuo, Jianping Shanghai, CN 18 97

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 15, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00